CHIKV VLP/adjuvant for Chikungunya (CHIKV VLP Trial)

"Unfortunately, this particular study is no longer recruiting patients as of October 12th, 2022. This is according to the clinicaltrials.gov listing, which was first posted on September 29th, 2021. There are, however, 8 other trials recruiting patients as we speak."

"At the moment, this medical trial has 49 patients. Potential participants can be found at the Lynn Institute of the Rockies in Colorado Springs, Optimal Research, LLC in Melbourne, Palm Beach Research Center in West Palm Beach, and other locations."

"The primary objective of this clinical trial is to measure the incidence of solicited Adverse Events (AE) over a period of 29 days. Secondary objectives include CHIKV SNA Geometric Mean Titers (GMTs) at Days 8, 15, and 183, Geometric Mean Fold Increase (GMFI) in CHIKV SNA titers from Day 1 to Days 8, 15, 22, and 183, and Number and percentage of subjects with CHIKV SNA titers at or above selected thresholds at Days 8, 15, 22, and 183."

"This clinical trial is seeking 3258 individuals who have contracted chikungunya fever and are aged between 12 and 64. The eligible patient population for this study is defined as follows: Male or female, 12 to <65 years of age., Women who are either: (i) Not of childbearing potential (CBP): pre-menarche, surgically sterile (at least six weeks post bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or post-menopausal (defined as a history of ≥12 consecutive months without menses prior to randomization in the absence of other path"

"The age demographic that this trial is looking to enroll are people who have not yet hit retirement age and are above 12 years old."

"The safety of CHIKV VLP/adjuvant is estimated to be a 3. This is based on the fact that this is a Phase 3 trial, which means that there is both evidence of efficacy and multiple rounds of data supporting safety."